Pharmacogenomics for the efficacy of platinum-based chemotherapy: Old drugs, new integrated perspective - 19/04/20
pages | 9 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Although some biomarkers have been identified, there is still a lack of platinum pharmacogenomics markers that could be implemented in practice. |
• | The response to platinum drugs is a multifactorial dynamic process involving genetic background, tumor evolution and gut microbes. |
• | A single marker could only explain the treatment failure of a small number of patients, and integration of predictive biomarkers is needed. |
Abstract |
Platinum-based chemotherapy remains the cornerstone of treatment for many malignancies. However, although therapeutic efficiency varies greatly among individuals, there is a lack of pharmacogenomic biomarkers that can be used in clinical settings to identify chemosensitive patients and allow stratification. With the development of high-throughput screening techniques and systems biology approaches, a growing body of evidence has shown that platinum resistance is a multifactorial, multi-dimensional, dynamic process incorporating genetic background, tumor evolution and gut microbes. This review critically summarizes potential pharmacogenomic biomarkers for predicting the efficacy of platinum drugs and provides a comprehensive, time-varying perspective that integrates multiple markers.
Le texte complet de cet article est disponible en PDF.Keywords : Pharmacogenomics, Platinum, Efficacy, Resistance, Biomarker
Plan
Vol 126
Article 110057- juin 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?